SARS-CoV-2 Nucleocapsid anticorps

N° du produit ABIN6952432

Cité dans 12+ publications. Cet anticorps anti-SARS-CoV-2 Nucleocapsid est un anticorps Monoclonal produit chez le Souris, détectant SARS-CoV-2 Nucleocapsid dans ELISA, WB et IF. Convient pour SARS Coronavirus-2 (SARS-CoV-2).

Aperçu rapide pour SARS-CoV-2 Nucleocapsid anticorps (ABIN6952432)

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reactivité: SARS Coronavirus-2 (SARS-CoV-2)

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SARS-CoV-2 Nucleocapsid est non-conjugé

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF)

Clone: 3851

Détail du produit anti-SARS-CoV-2 Nucleocapsid anticorps

Specificité: Specific for the nucleoprotein of the SARS virus.

Purification: SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.

Isotype: IgG2b

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: antibody can be stored at -20°C, stable for one year.

Date de péremption: 12 months

Références pour anticorps anti-SARS-CoV-2 Nucleocapsid (ABIN6952432)

Mirabelli, Bragazzi Cunha, Wotring, Sherman, El Saghir, Harder, Kretzler, Sexton, Emmer, Wobus: "ARF6 is a host factor for SARS-CoV-2 infection in vitro." dans: The Journal of general virology, Vol. 104, Issue 6, (2023) (PubMed).

Qiao, Wotring, Zhang, Jiang, Xiao, Watt, Gattis, Scandalis, Freier, Zheng, Pretto, Ellison, Swayze, Guo, Sexton, Chinnaiyan: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." dans: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).

Qiao, Wotring, Zheng, Zhang, Zhang, Jiang, Pretto, Eyunni, Parolia, He, Cheng, Cao, Wang, Su, Ellison, Wang, Qin, Yan, Zhou, Ma, Sexton, Chinnaiyan: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).

Wotring, Fursmidt, Ward, Sexton: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." dans: Journal of dairy science, (2022) (PubMed).

Sherman, Mirabelli, Tang, Khan, Leix, Kennedy, Graham, Willer, Tai, Sexton, Wobus, Emmer: "Identification of cell type specific ACE2 modifiers by CRISPR screening." dans: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).

Mirabelli, Sherman, Wotring, El Saghir, Bragazzi Cunha, Harder, Sexton, Emmer, Wobus: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." dans: bioRxiv : the preprint server for biology, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." dans: bioRxiv : the preprint server for biology, (2022) (PubMed).

Yao, Subedi, Liu, Khalasawi, Pretto-Kernahan, Wotring, Wang, Yin, Jiang, Fu, Dimitrion, Li, Veenstra, Yi, McKinnon, McKinnon, Sexton, Zhou, Mi: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." dans: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." dans: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Pretto, Qiao, Zhang, Frum, Kadambi, Amin, OMeara, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Chinnaiyan, Sexton: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).

Baang, Smith, Mirabelli, Valesano, Manthei, Bachman, Wobus, Adams, Washer, Martin, Lauring: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." dans: The Journal of infectious diseases, (2020) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Frum, Kadambi, Amin, OMeara, Pretto, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Sexton: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." dans: bioRxiv : the preprint server for biology, (2020) (PubMed).

Détails sur SARS-CoV-2 Nucleocapsid

Antigène: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Autre désignation: SARS-CoV-2 Nucleocapsid Protein

Classe de substances: Viral Protein